Home / Resources / Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

White paper
Clinical
Young female researcher working in the lab, examining samples under a microscope

Recent technological advancements like antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) have improved HER3’s targetability and pharmacological potential.

About the author

Headshot image of Domenique Catalano

Domenique Catalano

Oncology Trialtrove Analyst | Citeline

Domenique Catalano is an Oncology Trialtrove Analyst involved in various data enhancements and projects supporting the Ask the Analyst service. She engages in trial landscape analyses and expert subject matter queries in oncology. With extensive primary and secondary research experience in the clinical trial and pharmaceutical industry, Domenique joined Trialtrove in 2023. A graduate of West Chester University in Pennsylvania, Domenique completed a dual major with a BS in both chemistry (pharmaceutical product development) and biology (cell & molecular concentration) and attained her MBA in 2023.

Related products
Digital map showcasing the reach of Sitetrove, providing data from trial sites across the globe.
Sitetrove
The industry-leading suite of global clinical trial investigator and site intelligence
Professional using a laptop device to access Trialtrove for trial insights and strategy.
Trialtrove
The go-to resource for informing clinical trial strategy, design and execution
Professionals accessing Scrip for the latest industry news and developments to gain advantage on competition.
Scrip
Global pharmaceutical industry news that goes beyond the headlines

Related resources

Preview cover for "Antibody-drug Conjugates: ‘Magic Bullets’ Become Reality" white paper
JAN 24, 2025
White paper
Clinical

Antibody-drug Conjugates: 'Magic Bullets' Become Reality

Antibody-drug conjugates (ADCs) present a promising alternative to traditional therapies.

Cycle for the destruction of cancer cells
JUL 09, 2024
Article
Clinical

Disparities, Not Diversity, Surround CAR-T Cell Therapy

Despite the potential of Chimeric antigen receptor T cell therapy (CAR-T cell therapy), access remains highly restricted, particularly among minority and vulnerable populations.

PDF preview of the 2024 ASCO post conference report.
JUN 12, 2024
Report
Commercial

The Future of Oncology: Insights from ASCO 2024

Gain invaluable insights market announcements in the field of oncology with our comprehensive ASCO 2024 Report.

VIEW ALL